Situation: The nurse works in a hospital chemotherapy day unit that treats adults with solid tumors. Another client had complete surgical removal of a stage III (tumor 3, node 1, metastasis 0) colon cancer. He asks why he needs chemotherapy when all the tumor was removed. Which explanation is accurate?

Why adjuvant chemotherapy after complete resection of stage III colon cancer

Stage III colon cancer is defined by tumor invasion through the bowel wall and spread to regional lymph nodes (T3 N1 M0). The key word is N1: cancer cells have already traveled beyond the primary tumor into the lymphatic system. Even when the surgeon removes all visible tumor and the affected nodes, individual cancer cells or tiny clusters too small for imaging or pathology to detect may already be circulating or seeded in distant tissues. These are called micrometastases or minimal residual disease (MRD) ^[1][2].

Watch out! The client’s reasoning — “the tumor was completely removed, so no treatment is needed” — confuses macroscopic complete resection with microscopic cure. Surgical margins may be clear, but lymph node positivity is a marker that systemic spread has likely begun.

The purpose of adjuvant chemotherapy is not to treat visible disease; it is to eradicate occult micrometastases that remain after surgery, thereby reducing the likelihood of recurrence and potentially increasing cure rates. ^[1] This is why option 4 is accurate.

Option	Why it is incorrect
1. It replaces radiation, which the colon cannot receive	Radiation is not contraindicated for the colon in all cases; more importantly, the decision for chemotherapy is based on stage and nodal status, not on substituting for radiation. Adjuvant therapy for stage III colon cancer is systemic because the risk is systemic.
2. It prevents a new, separate polyp from forming in the colon	Chemotherapy does not prevent new polyp formation. Polyps are premalignant lesions arising from the mucosa; adjuvant chemotherapy targets already-disseminated malignant cells, not future mucosal changes.
3. It lowers tumor markers that stay high after surgery	After complete resection, tumor markers such as CEA typically fall. Adjuvant chemotherapy is not given primarily to normalize a persistently elevated marker; it is given to eliminate invisible residual disease even when markers are normal.
4. It destroys unseen cancer cells that may remain	Correct. This directly describes eradication of micrometastases or MRD [1][2].

Key point! The rationale for adjuvant chemotherapy in stage III colon cancer is the presence of node-positive disease (N1), which implies a high probability of occult systemic spread. The goal is to treat minimal residual disease, not the primary tumor that was already removed ^[1][2].

Current guidelines support an oxaliplatin-based regimen such as FOLFOX (5-fluorouracil plus oxaliplatin) or CapeOx (capecitabine plus oxaliplatin) for stage III colon cancer ^[1]. Emerging tools such as circulating tumor DNA (ctDNA) are being studied to detect MRD after surgery and refine which patients truly need adjuvant therapy, but the fundamental principle remains: adjuvant chemotherapy targets residual disease that conventional imaging and pathology cannot see. ^[2]